Physician profile
Scott T Phillips
NPI 1003840513
$17,229.20
in general payments reported to CMS, 2019-2025
43 companies · $2,547 in 2025
The $2,547 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,121 · 2020: $2,150 · 2021: $2,614 · 2022: $2,627 · 2023: $2,552 · 2024: $2,620 · 2025: $2,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,718.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,212.92 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,875.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,865.23 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,781.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,655.11 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $964.66 | 2019-2025 | Spravato, Xarelto |
| Abbvie INC. | $916.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $870.06 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $855.71 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Sanofi-Aventis U.S. LLC | $630.09 | 2019-2023 | |
| Edwards Lifesciences Corporation | $569.69 | 2023-2025 | |
| Amgen INC. | $482.72 | 2019-2025 | Repatha, Otezla, Evenity |
| E.R. Squibb & Sons, L.L.C. | $384.68 | 2019-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $244.91 | 2021-2024 | |
| Astellas Pharma US INC | $229.22 | 2019-2025 | Veozah, Myrbetriq |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $208.28 | 2022-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $201.86 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.62 | 2021-2025 | Xifaxan, Trulance |
| Allergan, INC. | $125.69 | 2020 | |
| Exact Sciences Corporation | $117.56 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $107.87 | 2021-2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $80.38 | 2024-2025 | Flucelvax, Fluad |
| Amarin Pharma, INC. | $70.10 | 2020-2021 | |
| Eisai INC. | $64.71 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $56.82 | 2019 | |
| Esperion Therapeutics, INC. | $54.33 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $54.15 | 2022 | |
| Radius Health, INC. | $50.11 | 2023-2024 | Tymlos |
| Horizon Therapeutics Plc | $46.33 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $38.04 | 2020 | |
| Boston Scientific Corporation | $33.08 | 2025 | Cds - Mct/Cem Monitoring |
| Sanofi Pasteur INC. | $29.86 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.74 | 2023 | Glassia |
| Pulmonx Corporation | $24.75 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Medtronic, INC. | $24.22 | 2025 | Inceptiv |
| Ibsa Pharma INC. | $23.91 | 2025 | Tirosint, Flector, Licart |
| Novartis Pharmaceuticals Corporation | $23.07 | 2019 | |
| Ardelyx, INC. | $18.12 | 2024 | Ibsrela |
| Lifescan, INC. | $17.36 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.67 | 2022 | |
| Acella Pharmaceuticals, LLC | $15.87 | 2025 | NP Thyroid 60 |
| Idorsia Pharmaceuticals US INC | $13.83 | 2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $13.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.